Therefore, further validation in study populations consisting of higher proportion of BRCA1- and BRCA2-deficient breast cancers, such as that in breast cancer cohorts enriched with a prior high-risk patients, may be warranted to assess the generalizability of our findings. The gene discussed is BRCA2; the disease is breast carcinoma.